Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • FDA, Moderna appear aligned on mRNA flu shot heading into adcomm
  • Regulatory

FDA, Moderna appear aligned on mRNA flu shot heading into adcomm

BioSpace

The Vaccines and Related Biological Products Advisory Committee will meet June 18 to discuss Moderna's seasonal flu vaccine mRNA-1010 after the FDA initially refused to accept the application in Febru

Infectious Disease

Read full story

pharminent June 16, 2026

BioSpace

The Vaccines and Related Biological Products Advisory Committee will meet June 18 to discuss Moderna’s seasonal flu vaccine mRNA-1010 after the FDA initially refused to accept the application in Febru

Infectious Disease

Read full story

Post navigation

Previous: German said to be backtracking on pharma rebate changes
Next: EHA26: BMS touts positive multiple myeloma data for two pipeline candidates

Related Stories

  • Regulatory

Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa

pharminent August 20, 2026
  • Regulatory

Regeneron wins FDA approval to challenge Ipsen for rare bone disease market

pharminent August 20, 2026
  • Regulatory

FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy

pharminent August 20, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.